[go: up one dir, main page]

UA99434C2 - Применение производных алкилфосфолипидов со сниженной цитотоксичностью - Google Patents

Применение производных алкилфосфолипидов со сниженной цитотоксичностью

Info

Publication number
UA99434C2
UA99434C2 UAA200808785A UAA200808785A UA99434C2 UA 99434 C2 UA99434 C2 UA 99434C2 UA A200808785 A UAA200808785 A UA A200808785A UA A200808785 A UAA200808785 A UA A200808785A UA 99434 C2 UA99434 C2 UA 99434C2
Authority
UA
Ukraine
Prior art keywords
reduced cytotoxicity
phospholipid derivatives
alkyl phospholipid
alkyl
derivatives
Prior art date
Application number
UAA200808785A
Other languages
English (en)
Ukrainian (uk)
Inventor
Даніель Перріссу
Матіас Пітрас
Юрген ЕНГЕЛЬ
Original Assignee
Аетерна Центаріс Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аетерна Центаріс Гмбх filed Critical Аетерна Центаріс Гмбх
Publication of UA99434C2 publication Critical patent/UA99434C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Представленное изобретение касается применения производных алкилфосфолипидов со сниженной цитотоксичностью для изготовления лекарственных средств, пригодных для лечения или профилактики заболеваний и/или патофизиологических состояний у млекопитающих, преимущественно людей, вызванных грибками, где применение может быть как в виде самостоятельных лекарственных средств, так и в комбинации с другими.
UAA200808785A 2005-12-19 2006-12-19 Применение производных алкилфосфолипидов со сниженной цитотоксичностью UA99434C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75143805P 2005-12-19 2005-12-19

Publications (1)

Publication Number Publication Date
UA99434C2 true UA99434C2 (ru) 2012-08-27

Family

ID=40214741

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200808785A UA99434C2 (ru) 2005-12-19 2006-12-19 Применение производных алкилфосфолипидов со сниженной цитотоксичностью

Country Status (4)

Country Link
US (1) US20070167408A1 (ru)
CN (1) CN101340918B (ru)
UA (1) UA99434C2 (ru)
ZA (1) ZA200804574B (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004012744A1 (de) * 2002-07-30 2004-02-12 Zentaris Gmbh Anwendung von alkylphosphocholinen in kombination mit antitumormedikamenten
US8383605B2 (en) * 2002-07-30 2013-02-26 Aeterna Zentaris Gmbh Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
DE102007014375A1 (de) * 2007-03-26 2008-10-02 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Oleylphosphocholin
US20130225479A1 (en) * 2010-08-27 2013-08-29 The University Of North Carolina At Chapel Hill Methods and Compositions for Treating Inflammation
WO2013119350A1 (en) * 2012-02-06 2013-08-15 Exxonmobil Upstream Research Company Method to determine location, size and in situ conditions in hydrocarbon reservoir with ecology, geochemistry, and biomarkers
EP2805612A1 (en) * 2013-05-22 2014-11-26 University of Graz Lysophospholipids against American Foulbrood
MX381235B (es) 2014-11-17 2025-03-12 Cellectar Biosciences Inc Análogos de éter fosfolipídico como portadores de fármacos dirigidos a cáncer.
US11186606B2 (en) * 2017-10-27 2021-11-30 Shanghai Yao Yuan Biotechnology Co., Ltd. Compositions and methods of modulating the immune response by activating alpha protein kinase 1
CN111187751A (zh) * 2020-01-19 2020-05-22 中国农业科学院兰州兽医研究所 一种用于构建幼畜心肌炎细胞模型的细胞系及构建方法
US20230320994A1 (en) * 2020-08-21 2023-10-12 The Board Of Regents Of The University Of Texas System Functional ionizable phospholipids
GR1010154B (el) * 2020-09-22 2022-01-19 Quadrel S.R.L., Ενωση για χρηση στη θεραπεια πρωτοζωικων ασθενειων και διαδικασια παραγωγης της εν λογω ενωσης
CN114377018B (zh) * 2020-10-21 2024-02-06 中国医学科学院药物研究所 硝呋莫司在制备抗流感病毒药物中的应用
CN115708408B (zh) * 2021-05-19 2025-02-25 中国医学科学院基础医学研究所 脂质小分子作为3c-样蛋白酶靶向剂在抗病毒方面的用途以及广谱抗炎作用
CN113813269B (zh) * 2021-10-15 2023-03-31 中国人民解放军空军军医大学 Perifosine在制备抗汉滩病毒药物中的应用
TW202410906A (zh) * 2022-05-20 2024-03-16 美商歐米伽治療公司 用於遞送治療劑的脂質

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0061872B1 (en) * 1981-03-30 1985-08-07 Takeda Chemical Industries, Ltd. Ethyleneglycol derivatives, their production and use
DE4111105A1 (de) * 1991-04-05 1992-10-08 Max Planck Gesellschaft Neue erucyl-, brassidyl- und nervonylderivate
ATE136783T1 (de) * 1991-07-04 1996-05-15 Asta Medica Ag Arzneimittel mit antineoplastischer wirkung enthaltend als wirkstoff octadecyl-(2-(n- methylpiperidino)-ethyl>-phosphat und verfahren zu dessen herstellung
DE4132344A1 (de) * 1991-09-27 1993-04-01 Max Planck Gesellschaft Verfahren zur herstellung eines arzneimittels zur oralen oder topischen verabreichung bei der behandlung von leishmaniasis
US6172050B1 (en) * 1992-07-11 2001-01-09 Asta Medica Aktiengesellschaft Phospholipid derivatives
US5679648A (en) * 1994-11-30 1997-10-21 The University Hospital Methods for the treatment and prevention of fungal infections by administration of 3'-deoxypurine nucleosides
DE19835611A1 (de) * 1998-08-06 2000-02-10 Max Planck Gesellschaft Neuartige Phospholipide mit synthetischen, ungesättigten Alkyl- und Acylketten
US7887817B2 (en) * 2002-01-25 2011-02-15 Aeterna Zentaris Gmbh Process for preventing protozoal diseases
DE60333903D1 (de) * 2002-02-20 2010-10-07 Ninkov Dusan Antimikrobielle therapeutische zusammensetzungen und ihre verwendung
WO2004012744A1 (de) * 2002-07-30 2004-02-12 Zentaris Gmbh Anwendung von alkylphosphocholinen in kombination mit antitumormedikamenten

Also Published As

Publication number Publication date
CN101340918A (zh) 2009-01-07
ZA200804574B (en) 2009-04-29
CN101340918B (zh) 2012-10-03
US20070167408A1 (en) 2007-07-19

Similar Documents

Publication Publication Date Title
UA99434C2 (ru) Применение производных алкилфосфолипидов со сниженной цитотоксичностью
WO2007071658A3 (en) Alkyl phospholipid derivatives with reduced cytotoxicity and uses thereof
MX349137B (es) Metodos y composiciones para el tratamiento de infecciones persistentes y cancer por inhibicion de la ruta de muerte celular programada (pd-1).
WO2018049152A8 (en) Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
CY1109985T1 (el) Αναστολεις πρωτεασωματος και μεθοδοι χρησης αυτων
JO3235B1 (ar) مركبات بيررولوبيريميدين و استعمالاتها
MY161495A (en) Virus like particle compositions and methods of use
TW200942552A (en) Combination therapy with c-Met and HER antagonists
EA200800269A1 (ru) Пищевые изделия со средствами доставки и способы их получения
IL219721A (en) Load reconstituted lipoprotein complex for use in the method of treating dyslipidemia, Load reconstituted lipoprotein complex containing apolipoprotein and lipid segment, and a pharmacist's preparation containing them
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
TW200806325A (en) Therapeutic uses of inhibitors of RTP801
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
PL2134704T3 (pl) Związki i kompozycje pełniące rolę modulatorów aktywności GPR119
IN2012DN02645A (ru)
MY147247A (en) Organic compounds and their uses
TW200509892A (en) Novel aminobenzophenone compounds
CR8696A (es) Beta-carbolinas utiles para tratar enfermedades inflamatorias
SA523440384B1 (ar) مركبات الفوسفوليبيدات واستخداماتها
MX2008008556A (es) Derivados de triterpenoquinonas y triterpenofenoles y su aplicacion para el tratamiento de tumores y enfermedades parasitarias.
MX2021015333A (es) Combinaciones de inhibidores para el tratamiento de enfermedades relacionadas con la expresion de dux4.
ATE549341T1 (de) Spiroketale
TW200744614A (en) Novel alkyl phospholipid derivatives with reduced cytotoxicity and used thereof
GB0410238D0 (en) Therapeutic agents
WO2005080549A3 (de) Trioxacarcine und deren verwendung gegen infektionskrankheiten